- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 38/20 - Interleukines
Détention brevets de la classe A61K 38/20
Brevets de cette classe: 5119
Historique des publications depuis 10 ans
|
257
|
331
|
422
|
424
|
511
|
455
|
497
|
430
|
364
|
214
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Iovance Biotherapeutics, Inc. | 371 |
98 |
| The Regents of the University of California | 20720 |
66 |
| Massachusetts Institute of Technology | 10239 |
58 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3299 |
53 |
| Immunitybio, Inc. | 507 |
51 |
| Altor BioScience, LLC | 79 |
50 |
| The Board of Trustees of the Leland Stanford Junior University | 6644 |
49 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3337 |
43 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2999 |
41 |
| Novartis AG | 10263 |
38 |
| Memorial Sloan-Kettering Cancer Center | 2038 |
36 |
| The Trustees of the University of Pennsylvania | 4414 |
35 |
| Nektar Therapeutics | 407 |
35 |
| Regeneron Pharmaceuticals, Inc. | 4698 |
35 |
| Bristol-myers Squibb Company | 4729 |
34 |
| Genentech, Inc. | 4099 |
31 |
| Genexine, Inc. | 109 |
31 |
| Dana-Farber Cancer Institute, Inc. | 2662 |
30 |
| Philogen S.p.A. | 126 |
30 |
| Xencor, Inc. | 412 |
30 |
| Autres propriétaires | 4245 |